Indication Expansion Dynamics and Trial Characteristics of Novel Multi-Indication Anti-Cancer Drugs in China (2000-2024): A Cross-Sectional Study.

Monoclonal antibodies such as trastuzumab and bevacizumab demonstrated a clear trend toward expanding indications beyond their initial approvals, targeting additional malignancies such as gastric, colorectal, and ovarian cancers.

also in 19,460 other papers

While the expansion of novel multi-indication anti-cancer drugs has become an established trend in the United States and Europe, with many drugs obtaining more supplemental indications within a few years after their initial approval, 17–20 China has started relatively late in this regard.

also in 56 other papers